Table 3.
Characteristics of Clinical Trials Related to Docetaxel
| Clinical Trials | Period | Number of Patients | Age, Yr, Median (IQR) | Control | Treatment | Median Follow-Up (months) | Median Overall Survival (months) | Median Time to Progression (months) |
|---|---|---|---|---|---|---|---|---|
| CHAARTED | 7, 2006–11,2012 | 790 | 64 (36–91) | ADT (LHRH agonist or LHRH antagonist) or surgical castration | ADT + Doc (75 mg/m2 every 3 weeks for 6 cycles) | 28.9 | (ADT 57.6; ADT + Doc 44; P<0.001) | (ADT 11.7; ADT + Doc 20.2; P<0.001) |
| STAMPEDEa | 9, 2005–3, 2013 | 1776 | 65 (40–82) | ADT (LHRH analogs or LHRH antagonists or bilateral orchiectomy) | ADT + Doc (75 mg/m2 every 3 weeks for 6 cycles+predisone) | 43 | (ADT 71; ADT + Doc 81; P=0.006) | __ |
| STAMPEDEb | 9, 2005–3, 2013 | 1186 | 66 (42–84) | ADT + ZA (4 mg every 3–4 weeks for 2 years) | ADT + ZA (4 mg every 3–4 weeks for 2 years) + Doc(75 mg/m2 every 3 weeks for 6 cycles + predisone) | 43 | (ADT + ZA) not reached; ADT + Doc 76 | __ |
| GETUG-15 | 10, 2004–12, 2008 | 385 | 63.5 (57–70) | ADT (LHRH agonist or surgical castration or combined androgen blockade) | ADT+Doc (75 mg/m2 every 3 weeks for up to 9 cycles) | 83.9 | (ADT 62.1; ADT + Doc 48.6; P=0.3) | (ADT 12.9; ADT + Doc 22.9; P<0.001) |
Notes: aADT with or without docetaxel, bADT plus zoledronic acid with or without docetaxel.
Abbreviations: IQR, interquartile range; ADT, androgen deprivation therapy; Doc, docetaxel; ZA, zoledronic acid; LHRH, luteinizing hormone releasing hormone.